The decision to fund medications to treat H.I.V.-AIDS patients in sub-Saharan Africa and the Caribbean flew in the face of expert advice. But the U.S. did it anyway.
Author: AMANDA TAUB
Advertisements
{
"slotId": "6845006044",
"unitType": "responsive",
"resize": "auto"
}